![]() |
|
|
Department of Biochemistry, University of California, Riverside, California 92502
Under conditions of chronic hypocalcemia, e.g. in vitamin D depletion, the parathyroid glands undergo marked hypertrophy and hyperplasia. Seven days of treatment (100 IU/day; 6.5 nmoles) with cholecalciferol (CC) decreased parathyroid gland weight significantly from vitamin D depleted controls while increasing serum Ca from 6.3 to 8.6 mg/100 ml. 1,25-Dihydroxycholecalciferol (1.3 nmoles/day) also increased serum Ca to 8.6, but had no effect on gland weight. Both CC and 1,25-dihydroxycholecalciferol stimulated the production of intestinal calcium binding protein. This same dose of 1,25-dihydroxycholecalciferol in combination with small amounts of 24R,25-dihydroxycholecalciferol was as effective as CC in reducing parathyroid gland weight, but 24R,25-dihydroxycholecalciferol alone had no effect on gland weight or on calcium binding protein synthesis. When chicks received a two- to four-fold larger dose of 1,25-dihydroxycholecalciferol, parathyroid gland weight was significantly reduced relative to vitamin D depleted controls. A time course of the action of CC indicated that 4 days treatment was sufficient for significant parathyroid gland size reduction. Decreases in gland wet weight caused by CC were paralleled by decreases in dry weight, and loss of DNA and protein. It is concluded that parathyroid gland regression, involving loss of cells, occurs within a few days of treatment with vitamin D metabolites and that gland regression does not obligatorily follow an increase in serum Ca. At low doses, 1,25-dihydroxycholecalciferol requires the presence of 24R,25-dihydroxycholecalciferol to cause gland regression (but not intestinal calcium binding protein production), whereas it is effective alone at higher doses. These results suggest that the dihydroxylated vitamin D metabolites may play a role in modulating parathyroid gland as well as intestinal function.
KEY WORDS: 24,25-dihydroxycholecalciferol 1,25-dihydroxycholecalciferol parathyroid glands cholecalciferol
1 This work was supported in part by grant from the National Institute of Arthritis and Metabolic Diseases (AM-09012, AM-14750 and AM-04652). It was presented in part at the 1976 meeting of the Federation of American Societies for Experimental Biology, Anaheim, Calif., April, 1976 (Federation Proc. 35, 340) and at the International Congress of Endocrinology in Hamburg, Germany, July, 1976.
2 Department of Microscopic Anatomy, Baylor College of Dentistry, Dallas, Texas. 75226.
3 Recipient of United States Public Health Service Career Research Development Award 1-ROK-AM-13, 654.
Manuscript received 28 December 1976.
This article has been cited by other articles:
![]() |
T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF] |
||||
![]() |
K. Olgaard and E. Lewin Can Hyperparathyroid Bone Disease Be Arrested or Reversed? Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 367 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Ameenuddin, M Sunde, H. DeLuca, N Ikekawa, and Y Kobayashi 24-hydroxylation of 25-hydroxyvitamin D3: is it required for embryonic development in chicks? Science, July 30, 1982; 217(4558): 451 - 452. [Abstract] [PDF] |
||||
![]() |
A. Norman, J. Frankel, A. Heldt, and G. Grodsky Vitamin D deficiency inhibits pancreatic secretion of insulin Science, August 15, 1980; 209(4458): 823 - 825. [Abstract] [PDF] |
||||
![]() |
H. Henry and A. Norman Vitamin D: two dihydroxylated metabolites are required for normal chicken egg hatchability Science, September 1, 1978; 201(4358): 835 - 837. [Abstract] [PDF] |
||||